No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.
Why the path to HCV elimination must reach PWID.
We must stay the course to eliminate HBV as a public health threat.
How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.
How can providers ensure that vulnerable populations are linked to HCV testing and care? Here’s my take on what we should be doing in our practice.
Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.